PL1830872T3 - Białka fuzyjne - Google Patents

Białka fuzyjne

Info

Publication number
PL1830872T3
PL1830872T3 PL05810103T PL05810103T PL1830872T3 PL 1830872 T3 PL1830872 T3 PL 1830872T3 PL 05810103 T PL05810103 T PL 05810103T PL 05810103 T PL05810103 T PL 05810103T PL 1830872 T3 PL1830872 T3 PL 1830872T3
Authority
PL
Poland
Prior art keywords
fusion proteins
fusion
proteins
Prior art date
Application number
PL05810103T
Other languages
English (en)
Inventor
Keith Foster
John Chaddock
Philip Marks
Patrick Stancombe
K Roger Aoki
Joseph Francis
Lance Steward
Original Assignee
Sec Dep For Health
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0426394A external-priority patent/GB0426394D0/en
Application filed by Sec Dep For Health, Allergan Inc filed Critical Sec Dep For Health
Publication of PL1830872T3 publication Critical patent/PL1830872T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
PL05810103T 2004-12-01 2005-12-01 Białka fuzyjne PL1830872T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0426394A GB0426394D0 (en) 2004-12-01 2004-12-01 Fusion proteins
GB0504964A GB0504964D0 (en) 2004-12-01 2005-03-10 Fusion proteins
EP05810103A EP1830872B1 (en) 2004-12-01 2005-12-01 Fusion proteins
PCT/GB2005/004585 WO2006059093A2 (en) 2004-12-01 2005-12-01 Fusion proteins

Publications (1)

Publication Number Publication Date
PL1830872T3 true PL1830872T3 (pl) 2011-09-30

Family

ID=35745992

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05810103T PL1830872T3 (pl) 2004-12-01 2005-12-01 Białka fuzyjne

Country Status (5)

Country Link
EP (1) EP1830872B1 (pl)
AU (1) AU2005311086B2 (pl)
CA (1) CA2595115C (pl)
PL (1) PL1830872T3 (pl)
WO (1) WO2006059093A2 (pl)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
DE60032367T3 (de) 1999-08-25 2011-03-10 Allergan, Inc., Irvine Aktivierbare rekombinante neurotoxine
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
DE602005011458D1 (de) 2004-09-01 2009-01-15 Allergan Inc Abbaubare clostridientoxine
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
WO2006099590A2 (en) 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
AU2006339490B2 (en) 2005-09-19 2011-12-08 Allergan, Inc. Clostridial toxin activatable clostridial toxins
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2011202219B2 (en) * 2005-12-01 2015-05-28 Allergan Inc. Fusion proteins
AU2011202225B2 (en) * 2005-12-01 2015-08-20 Allergan, Inc. Non-cytotoxic protein conjugates
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
EP2505592A1 (en) 2006-07-11 2012-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
CA2658260A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
NZ585108A (en) * 2007-10-23 2012-09-28 Allergan Inc Methods of treating urogenital-neurological disorders using modified clostridial toxins
BRPI0819212A2 (pt) * 2007-10-23 2015-06-16 Allergan Inc Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
WO2009150470A2 (en) * 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
EP2310028B1 (en) * 2008-06-12 2016-11-16 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
RU2535003C2 (ru) 2008-12-10 2014-12-10 Аллерган, Инк. Фармацевтические композиции токсина клостридий
WO2010105236A1 (en) 2009-03-13 2010-09-16 Allergan, Inc. Immuno-based retargeted endopeptidase activity assays
US20100303757A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303794A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
WO2011020119A2 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
EP2464365A2 (en) 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
US20110064713A1 (en) 2009-08-14 2011-03-17 Allergan, Inc. Methods of Treating Cancer Using Opioid Retargeted Endopepidases
WO2011020056A2 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using galanin retargeted endpeptidases
WO2011020115A2 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using growth factor retargeted endopeptidases
EP2464367A2 (en) 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using neurotrophin retargeted endopeptidases
JP2013514091A (ja) * 2009-12-16 2013-04-25 アラーガン、インコーポレイテッド 組込型プロテアーゼ切断部位結合ドメインを含む改変クロストリジウム毒素
US20120207743A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
WO2012112422A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using growth factor retargeted endopeptidases
WO2012112426A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Arginine vasopressin retargeted clostridial endopeptidases for use in treating benign prostatic hyperplasia
WO2012112432A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
BR112023018473A2 (pt) 2021-03-30 2023-11-14 Ipsen Biopharm Ltd Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios
BR112023020057A2 (pt) 2021-03-30 2024-03-12 Ipsen Biopharm Ltd Tratamento de dor e distúrbios inflamatórios
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
CN115927263A (zh) * 2022-12-13 2023-04-07 中国药科大学 一种IgA蛋白酶及其制备方法
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DE19642043A1 (de) 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
ITMI20022022A1 (it) * 2002-09-24 2004-03-25 Girolamo Calo' Analoghi di nocicettina.
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates

Also Published As

Publication number Publication date
WO2006059093A3 (en) 2006-08-17
EP1830872B1 (en) 2010-11-17
CA2595115A1 (en) 2006-06-08
AU2005311086B2 (en) 2012-03-29
EP1830872A2 (en) 2007-09-12
AU2005311086A1 (en) 2006-06-08
WO2006059093A2 (en) 2006-06-08
CA2595115C (en) 2014-01-21

Similar Documents

Publication Publication Date Title
GB0426397D0 (en) Fusion proteins
IL176894A0 (en) Albumin fusion proteins
IL189246A0 (en) Albumin fusion proteins
EP1934372A4 (en) SSB-POLYMERASE HYBRID PROTEINS
ZA200801224B (en) Albumin fusion proteins
GB0423974D0 (en) Proteins
GB0417887D0 (en) Protein
GB0426399D0 (en) Fusion proteins
GB0423002D0 (en) Proteins
GB0404929D0 (en) Protein
GB0401882D0 (en) Protein
GB0416035D0 (en) Protein
GB0405885D0 (en) Proteins
GB0405643D0 (en) Proteins
GB0411678D0 (en) Proteins
GB0412570D0 (en) Proteins
GB0415161D0 (en) Proteins
GB0418666D0 (en) Proteins
GB0418248D0 (en) Proteins
AU2005905300A0 (en) Fusion Protein
GB0402662D0 (en) Protein
GB0408217D0 (en) Protein
GB0403142D0 (en) Protein
GB0405057D0 (en) Protein
GB0402811D0 (en) Protein